National Research Corp (NASDAQ:NRCIB) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. National Research Corp provides analytics and insights that improves measurement and improvement of the patient and employee experience. Its subscription-based solutions provide actionable information and analysis to healthcare organizations. National Research Corp has a market cap of $837.200 million; its shares were traded at around $50.86 with a P/E ratio of 16.00 and P/S ratio of 3.13. The dividend yield of National Research Corp stocks is 4.72%. National Research Corp had annual average EBITDA growth of 2.10% over the past ten years.
For the last quarter National Research Corp reported a revenue of $29.9 million, compared with the revenue of $28.37 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $117.6 million, an increase of 7.5% from last year. For the last five years National Research Corp had an average revenue growth rate of 6.1% a year.
Top 5 Stocks To Own For 2019: Realogy Holdings Corp.(RLGY)
Advisors' Opinion:- [By Max Byerly]
Old Mutual Global Investors UK Ltd. trimmed its holdings in Realogy Holdings Corp (NYSE:RLGY) by 11.2% in the first quarter, HoldingsChannel.com reports. The fund owned 2,142,930 shares of the financial services provider’s stock after selling 269,939 shares during the period. Old Mutual Global Investors UK Ltd.’s holdings in Realogy were worth $58,459,000 at the end of the most recent quarter.
- [By Ethan Ryder]
Realogy Holdings Corp (NYSE:RLGY)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $20.02 and last traded at $21.29, with a volume of 184103 shares changing hands. The stock had previously closed at $21.82.
- [By Stephan Byrd]
Realogy Holdings Corp (NYSE:RLGY) has been given an average recommendation of “Hold” by the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $32.29.
- [By Max Byerly]
Get a free copy of the Zacks research report on Realogy (RLGY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
Realogy (NYSE:RLGY) had its target price trimmed by Citigroup from $37.00 to $35.00 in a report released on Friday morning. The firm currently has a buy rating on the financial services provider’s stock.
Top 5 Stocks To Own For 2019: Camden Property Trust(CPT)
Advisors' Opinion:- [By Max Byerly]
Amundi Pioneer Asset Management Inc. lifted its holdings in Camden Property Trust (NYSE:CPT) by 8.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 291,582 shares of the real estate investment trust’s stock after acquiring an additional 21,627 shares during the period. Amundi Pioneer Asset Management Inc. owned approximately 0.31% of Camden Property Trust worth $24,545,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Stephan Byrd]
Camden Property Trust (NYSE:CPT) announced a quarterly dividend on Friday, June 15th, RTT News reports. Stockholders of record on Friday, June 29th will be given a dividend of 0.77 per share by the real estate investment trust on Tuesday, July 17th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date of this dividend is Thursday, June 28th.
- [By Max Byerly]
Concepta PLC (LON:CPT)’s share price hit a new 52-week low during trading on Thursday . The company traded as low as GBX 2.20 ($0.03) and last traded at GBX 2.35 ($0.03), with a volume of 310160 shares. The stock had previously closed at GBX 2.65 ($0.03).
- [By Ethan Ryder]
Swiss National Bank reduced its position in Camden Property Trust (NYSE:CPT) by 5.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 451,000 shares of the real estate investment trust’s stock after selling 28,000 shares during the quarter. Swiss National Bank’s holdings in Camden Property Trust were worth $37,965,000 as of its most recent filing with the SEC.
- [By Stephan Byrd]
These are some of the news articles that may have impacted Accern Sentiment’s rankings:
Get Camden Property Trust alerts: Camden Property Trust to Post Q3 2018 Earnings of $1.19 Per Share, DA Davidson Forecasts (CPT) (americanbankingnews.com) Camden Property Trust Forecasted to Earn FY2019 Earnings of $4.99 Per Share (CPT) (americanbankingnews.com) Camden Property Trust’s (CPT) CEO Ric Campo on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) Edited Transcript of CPT earnings conference call or presentation 4-May-18 3:00pm GMT (finance.yahoo.com) Camden: 1Q Earnings Snapshot (finance.yahoo.com)Several research firms have commented on CPT. BTIG Research increased their price target on shares of Camden Property Trust to $93.00 and gave the company a “buy” rating in a research report on Thursday, March 15th. Zacks Investment Research raised shares of Camden Property Trust from a “sell” rating to a “hold” rating in a research report on Tuesday, March 20th. TheStreet lowered shares of Camden Property Trust from a “b” rating to a “c+” rating in a research report on Thursday, January 18th. Sandler O’Neill set a $97.00 price target on shares of Camden Property Trust and gave the company a “buy” rating in a research report on Tuesday, February 6th. Finally, BMO Capital Markets set a $94.00 price target on shares of Camden Property Trust and gave the company a “buy” rating in a research report on Monday, February 12th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $90.64.
- [By Shane Hupp]
News articles about Camden Property Trust (NYSE:CPT) have trended positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Camden Property Trust earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned media coverage about the real estate investment trust an impact score of 47.1765126263188 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Top 5 Stocks To Own For 2019: ClearBridge American Energy MLP Fund Inc.(CBA )
Advisors' Opinion:- [By Ethan Ryder]
News headlines about ClearBridge American Energy MLP Fund (NYSE:CBA) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ClearBridge American Energy MLP Fund earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the investment management company an impact score of 47.3026009142931 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
- [By Max Byerly]
Sit Investment Associates Inc. grew its position in shares of ClearBridge American Energy MLP Fund Inc (NYSE:CBA) by 20.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 795,051 shares of the investment management company’s stock after acquiring an additional 136,834 shares during the quarter. Sit Investment Associates Inc. owned 1.36% of ClearBridge American Energy MLP Fund worth $6,003,000 at the end of the most recent reporting period.
Top 5 Stocks To Own For 2019: Pershing Gold Corporation(PGLC)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on Pershing Gold (PGLC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on Pershing Gold (PGLC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on Pershing Gold (PGLC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Pershing Gold (PGLC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Stocks To Own For 2019: Madrigal Pharmaceuticals, Inc. (MDGL)
Advisors' Opinion:- [By Lisa Levin] Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares surged 144.96 percent to close at $265.61 on Thursday in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks. Viking Therapeutics, Inc. (NASDAQ: VKTX) shares rose 101.01 percent to close at $9.99 on Thursday after falling 4.42 percent on Wednesday. Akers Biosciences, Inc. (NASDAQ: AKER) jumped 45.58 percent to close at $0.474. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days. Kitov Pharma Ltd (NASDAQ: KTOV) gained 40.93 percent to close at $3.03 after the FDA approved Kitov's Consensi for the treatment of osteoarthritis pain and hypertension. China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 28.21 percent to close at $19.86. J.Jill, Inc. (NYSE: JILL) climbed 26.45 percent to close at $7.84 after the company posted upbeat quarterly earnings. Curis, Inc. (NASDAQ: CRIS) shares climbed 21.93 percent to close at $2.78 in reaction to an encouraging FDA update. The biotechnology company that focuses on therapies for the treatment of cancer said the FDA granted a Fast Track designation for fimepinostat (CUDC-907) in patients with relapsed or refractory. Boxlight Corporation (NASDAQ: BOXL) gained 21.23 percent to close at $7.48. Kirkland's, Inc. (NASDAQ: KIRK) rose 16.21 percent to close at $12.83 after reporting upbeat Q1 results. The Brink's Company (NYSE: BCO) jumped 16.2 percent to close at $79.25 as the company announced plans to acquire Dunbar Armored for $520 million in cash. Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 15.14 percent to c
- [By George Budwell]
Viking's shares are soaring in response to a positive mid-stage result for its experimental nonalcoholic steatohepatitis (NASH) medicine VK2809. Most critically, the drug seems to compare favorably to Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196 in terms of both safety and efficacy.
- [By Keith Speights]
Viking stock received a huge boost recently thanks to great results reported by Madrigal Pharmaceuticals (NASDAQ:MDGL) from its phase 2 study of NASH candidate MGL-3196. Because Madrigal's drug uses the same mechanism of action as VK2809, expectations are high for similar success for Viking's phase 2 study.
- [By Shane Hupp]
Madrigal Pharmaceuticals (NASDAQ:MDGL)‘s stock had its “buy” rating restated by investment analysts at Cowen in a research note issued on Thursday.
- [By George Budwell]
Second, Vikings shares got a boost from the positive midstage trial results for Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196 not long ago. As VK2809 and MGL-3196 share a similar mechanism of action, Wall Street apparently believes MGL-3196's midstage results will turn out to be a preview for VK2809's midstage trial that's scheduled to readout later this year. While speculative, the bottom line here is that Viking could be developing a drug capable of generating over $1 billion in annual sales at its peak. That's a sizable revenue stream for a company with a market cap of only $617 million right now.
- [By Keith Speights]
The biggest reason why I think so highly of Viking Therapeutics' prospects is that I also think highly of Madrigal Pharmaceuticals' (NASDAQ:MDGL) prospects. In May, Madrigal announced really good results from a phase 2 clinical study of its lead candidate MGL-3196 in treating non-alcoholic steatohepatitis (NASH).
No comments:
Post a Comment